363 related articles for article (PubMed ID: 17342308)
1. KL-6 mucin is a useful immunohistochemical marker for cholangiocarcinoma.
Tang W; Guo Q; Qu X; Inagaki Y; Seyama Y; Midorikawa Y; Gai R; Kokudo N; Sugawara Y; Nakata M; Makuuchi M
Oncol Rep; 2007 Apr; 17(4):737-41. PubMed ID: 17342308
[TBL] [Abstract][Full Text] [Related]
2. Expression of KL-6 mucin, a human MUC1 mucin, in intrahepatic cholangiocarcinoma and its potential involvement in tumor cell adhesion and invasion.
Xu HL; Inagaki Y; Seyama Y; Sugawara Y; Kokudo N; Nakata M; Wang FS; Tang W
Life Sci; 2009 Aug; 85(9-10):395-400. PubMed ID: 19631667
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological characteristics of 15 patients with combined hepatocellular carcinoma and cholangiocarcinoma.
Zuo HQ; Yan LN; Zeng Y; Yang JY; Luo HZ; Liu JW; Zhou LX
Hepatobiliary Pancreat Dis Int; 2007 Apr; 6(2):161-5. PubMed ID: 17374575
[TBL] [Abstract][Full Text] [Related]
4. The alphavbeta6 integrin is a highly specific immunohistochemical marker for cholangiocarcinoma.
Patsenker E; Wilkens L; Banz V; Osterreicher CH; Weimann R; Eisele S; Keogh A; Stroka D; Zimmermann A; Stickel F
J Hepatol; 2010 Mar; 52(3):362-9. PubMed ID: 20137822
[TBL] [Abstract][Full Text] [Related]
5. Elevation of serum KL-6 mucin levels in patients with cholangiocarcinoma.
Xu H; Inagaki Y; Tang W; Guo Q; Wang F; Seyama Y; Midorikawa Y; Gai R; Kokudo N; Sugawara Y; Nakata M; Makuuchi M
Hepatogastroenterology; 2008; 55(88):2000-4. PubMed ID: 19260467
[TBL] [Abstract][Full Text] [Related]
6. KL-6 mucin in metastatic liver cancer tissues from primary colorectal carcinoma.
Zhang K; Tang W; Qu X; Guo Q; Inagaki Y; Seyama Y; Abe H; Gai R; Kokudo N; Sugawara Y; Nakata M; Makuuchi M
Hepatogastroenterology; 2009; 56(93):960-3. PubMed ID: 19760920
[TBL] [Abstract][Full Text] [Related]
7. [Clinicopathologic features and diagnosis of mixed type hepatocellular carcinoma].
Lu J; Lin Z; Yuan S
Zhonghua Zhong Liu Za Zhi; 1995 May; 17(3):208-11. PubMed ID: 7656828
[TBL] [Abstract][Full Text] [Related]
8. The utility of hepatocyte paraffin 1 antibody in the immunohistological distinction of hepatocellular carcinoma from cholangiocarcinoma and metastatic carcinoma.
Shiran MS; Isa MR; Sherina MS; Rampal L; Hairuszah I; Sabariah AR
Malays J Pathol; 2006 Dec; 28(2):87-92. PubMed ID: 18376797
[TBL] [Abstract][Full Text] [Related]
9. Combined hepatocellular and cholangiocarcinoma: clinical features and prognostic study in a Thai population.
Chantajitr S; Wilasrusmee C; Lertsitichai P; Phromsopha N
J Hepatobiliary Pancreat Surg; 2006; 13(6):537-42. PubMed ID: 17139428
[TBL] [Abstract][Full Text] [Related]
10. Utilization of antihepatocyte clone OCH1E5 (Hep Par 1) in histological evaluation of liver tumors.
Amarapurkar AD; Rege JD; Joshi AS; Vaiphei K; Amarapurkar DN
Indian J Pathol Microbiol; 2006 Jul; 49(3):341-4. PubMed ID: 17001880
[TBL] [Abstract][Full Text] [Related]
11. Cytoplasmic staining of TTF-1 in the differential diagnosis of hepatocellular carcinoma vs cholangiocarcinoma and metastatic carcinoma of the liver.
Lei JY; Bourne PA; diSant'Agnese PA; Huang J
Am J Clin Pathol; 2006 Apr; 125(4):519-25. PubMed ID: 16627262
[TBL] [Abstract][Full Text] [Related]
12. Management of combined hepatocellular and cholangiocarcinoma.
Kassahun WT; Hauss J
Int J Clin Pract; 2008 Aug; 62(8):1271-8. PubMed ID: 18284443
[TBL] [Abstract][Full Text] [Related]
13. Combined hepatocellular carcinoma and cholangiocarcinoma: clinical features, treatment modalities, and prognosis.
Yin X; Zhang BH; Qiu SJ; Ren ZG; Zhou J; Chen XH; Zhou Y; Fan J
Ann Surg Oncol; 2012 Sep; 19(9):2869-76. PubMed ID: 22451237
[TBL] [Abstract][Full Text] [Related]
14. Comparative immunohistochemical expression of p63 in human cholangiocarcinoma and hepatocellular carcinoma.
Ramalho FS; Ramalho LN; Della Porta L; Zucoloto S
J Gastroenterol Hepatol; 2006 Aug; 21(8):1276-80. PubMed ID: 16872309
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic significance of aquaporin-1 in liver tumors.
Mazal PR; Susani M; Wrba F; Haitel A
Hum Pathol; 2005 Nov; 36(11):1226-31. PubMed ID: 16260277
[TBL] [Abstract][Full Text] [Related]
16. [Evaluation of immunohistochemical markers for differential diagnosis of hepatocellular carcinoma from intrahepatic cholangiocarcinoma].
Dong H; Cong WL; Zhu ZZ; Wang B; Xian ZH; Yu H
Zhonghua Zhong Liu Za Zhi; 2008 Sep; 30(9):702-5. PubMed ID: 19173916
[TBL] [Abstract][Full Text] [Related]
17. Histologic differentiation of hepatocellular carcinoma from adenocarcinoma by a simple panel: evaluation of the pitfalls.
Geramizadeh B; Boub R; Rahsaz M
Indian J Pathol Microbiol; 2007 Jul; 50(3):507-10. PubMed ID: 17883119
[TBL] [Abstract][Full Text] [Related]
18. Intrahepatic cholangiocarcinoma diagnosed preoperatively as hepatocellular carcinoma.
Yamamoto M; Ariizumi S; Otsubo T; Katsuragawa H; Katagiri S; Nakano M; Takasaki K
J Surg Oncol; 2004 Aug; 87(2):80-3; discussion 83-4. PubMed ID: 15282700
[TBL] [Abstract][Full Text] [Related]
19. Expression of MUC1 and MUC2 mucin antigens in intrahepatic bile duct tumors: its relationship with a new morphological classification of cholangiocarcinoma.
Higashi M; Yonezawa S; Ho JJ; Tanaka S; Irimura T; Kim YS; Sato E
Hepatology; 1999 Dec; 30(6):1347-55. PubMed ID: 10573510
[TBL] [Abstract][Full Text] [Related]
20. Canalicular immunostaining of aminopeptidase N (CD13) as a diagnostic marker for hepatocellular carcinoma.
Röcken C; Licht J; Roessner A; Carl-McGrath S
J Clin Pathol; 2005 Oct; 58(10):1069-75. PubMed ID: 16189153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
